Navigation Links
Sangamo Announces Pricing of Public Offering of Common Stock
Date:10/7/2009

RICHMOND, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced the pricing of a public offering of 3,000,000 shares of its common stock. The offering is expected to close on or about October 13, 2009, subject to the satisfaction of customary closing conditions. In addition, Sangamo has granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any.

Jefferies & Company, Inc. is acting as sole book-running manager in this offering.

A registration statement relating to the shares of common stock issued in the offering has been filed with, and declared effective by, the Securities and Exchange Commission (the "SEC")." A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement relating to this offering, when available, may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022 or at (888) 449-2342. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic((TM)) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety an
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
2. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
3. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
4. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
5. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference
7. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
8. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
9. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
10. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
11. Sangamo BioSciences Initiates Phase 1 Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Nearly 20,000 medical professionals and healthcare leaders ... Clinical Lab Expo in Chicago ... diagnostic research and technology that will advance medicine and ... of Wednesday, July 30, more than 19,500 attendees had ... Lab Expo, with more than 10,000 of these attendees ...
(Date:7/31/2014)... mapped the sound-processing part of the mouse brain in ... the trees in view. Their imaging technique allows zooming ... mice, and it enabled the team to watch brain ... The results, which represent a step toward better understanding ... 31 the journal Neuron . , In the ...
(Date:7/31/2014)... 2014 Rogne Bioscience, a privately-held biotechnology company ... , has acquired a licence to anti-inflammatory peptides from ... potent anti-inflammatory activity of the peptides was discovered by ... Oxford,s Sir William Dunn School of Pathology. ... $1.5 million in seed financing, is developing a first-in-class, ...
(Date:7/31/2014)... , July 31, 2014 Research ... "Global Genomics Market 2014-2018" report to their ... Genomics is the study of the genetic material ... be a strong basis for the discovery and development ... human diseases or health conditions. Genomics is supported by ...
Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... 28 Pharmacopeia,(Nasdaq: PCOP ), an innovator ... therapeutics, today announced advancements for two members,of its ... and,Regulatory Affairs, has been promoted to Senior Vice ... S. David Kimball, Ph.D., Senior,Vice President, Chemistry and ...
... DIEGO, Feb. 28 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... a,Phase I study of ANA773, the company,s oral TLR7 ... trial is a safety,and tolerability study designed to identify ... to select the dose and,schedule for Phase II trials., ...
... report in the February 28, 2008, New England Journal ... Newborn Screening Program (NENSP) of the University of Massachusetts ... genetic disease, providing what may be the first demonstration ... , The state of Massachusetts has offered universal ...
Cached Biology Technology:Pharmacopeia Announces Management Team Changes 2Pharmacopeia Announces Management Team Changes 3Pharmacopeia Announces Management Team Changes 4Pharmacopeia Announces Management Team Changes 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4Data show a decline in cystic fibrosis since introduction of prenatal carrier screening 2
(Date:7/31/2014)... beneath many of the roughly 156,000 gas stations ... corrosion in parts of underground gas storage tankscorrosion ... of groundwater, a source of drinking water. In ... reported many rapidly corroding gas storage tank components ... associated with use of gasoline-ethanol blends and the ...
(Date:7/31/2014)... models against the highly infectious and virulent bacterium, ... kills approximately 30,000 Americans annually. The research is published ... , In the study, the vaccine protected the ... by C. difficile , as well as from ... the human disease, after only two immunizations. , ...
(Date:7/31/2014)... has been made to help better identify and treat those ... narrowing and enlarging of medium sized arteries in the body, ... organs causing damage. In a new report appearing in August ... scientists provide evidence that that FMD may not be limited ... a connection to abnormalities of bones and joints, as well ...
Breaking Biology News(10 mins):NIST corrosion lab tests suggest need for underground gas tank retrofits 2C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2
... and 17 September, in the context of France,s presidency ... GMES 2008, at the Grand Palais. The GMES ... set up to provide services relating to the environment, ... services draw on data - mainly Earth observation data ...
... for oceanic vessels has been impeded by worldwide concerns ... gas emissions that impact the Earth,s climate. A ... examines "Emission Tradeoffs among Alternative Marine Fuels: Total Fuel ... Marine Diesel Oil," in a recent issue of ...
... The 2009 Force Protection Equipment,Demonstration (FPED VII) ... VA, and Marine Corps Base, Quantico, VA, next ... Global War on Terror., The demonstration is ... of commercial off-the-shelf equipment solutions to current,and evolving ...
Cached Biology News:Major European program for the environment under the spotlight in Lille, France 2Fuel emissions from marine vessels remain a global concern 22009 Force Protection Equipment Demonstration Set for Next May 19-21 2
... The epitope is specific for Kir2.1 ... other known protein.,SPECIES REACTIVITIES: The ... bovine, porcine and guinea pig. It ... mouse (17/19 residues) and chick (15/19 ...
... Glutamate is the main excitatory neurotransmitter ... had been considered to act only on ... kainate receptors that are involved in the ... been shown to regulate enzymes producing second ...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
PMA (YPMA-1)...
Biology Products: